Commercial Supply Clofarabine Related Intermediates:
Clofarabine CAS: 123318-82-1
2-Deoxy-2-fluoro-1,3,5-tri-O-benzoyl-α-D-arabinofuranose CAS: 97614-43-2
β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS: 6974-32-9
1,3,5-Tri-O-benzoyl-D-Ribofuranose CAS: 22224-41-5
2,6-Dichloropurine CAS: 5451-40-1
| Chemical Name | 1,3,5-Tri-O-benzoyl-D-Ribofuranose |
| CAS Number | 22224-41-5 |
| CAT Number | RF-PI223 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C26H22O8 |
| Molecular Weight | 462.45 |
| Melting Point | 125.0-129.0℃(lit.) |
| Solubility | Insoluble in Water |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Off-White Powder |
| Purity | ≥99.0% |
| Loss on Drying | ≤1.00% |
| Maximum Single Impurity | ≤0.50% |
| Total Impurities | ≤1.00% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Clofarabine (CAS: 123318-82-1) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
1,3,5-Tri-O-benzoyl-D-Ribofuranose (CAS: 22224-41-5) is a starting material for nucleoside synthesis. It can be used as an intermediate of Clofarabine (CAS: 123318-82-1). Clofarabine is a novel purine nucleoside anticancer drugs is first successfully developed by the Top10 biopharmaceutical company of the United States-Genzyme Corporation with the trade names being “Clofarabine”. On December 28, 2004 the FDA used fast-track for approval of Clofarabine for application to children with refractory or relapsed acute lymphocytic leukemia. Clofarabine combines the advantages of Fludarabine and Cladribine to inhibit both DNA polymerase and RIbonucleic acid reductase. It is currently the only drug suitable for the treatment of childhood leukemia. Studies have proved that its therapeutic efficiency is very high, and the total response rate of patients with no response to two conventional chemotherapy is 31%. And patient tolerance is good, no unpredictable adverse reactions; It has potentially broad-spectrum antitumor properties.